Algert Global LLC Reduces Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Algert Global LLC reduced its holding in Hims & Hers Health by 36.4% in Q1, now owning 54,810 shares valued at approximately $1.62 million.
• CEO Andrew Dudum sold 128,127 shares at an average price of $45.06, resulting in a 58.87% decrease in his position.
• Hims & Hers Health's recent quarterly earnings report showed an EPS of $0.17, missing analysts' expectations and marking a 9.63% profit margin.

Algert Global LLC cut its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 36.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,810 shares of the company's stock after selling 31,330 shares during the period. Algert Global LLC's holdings in Hims & Hers Health were worth $1,620,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Signaturefd LLC lifted its position in Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC lifted its position in Hims & Hers Health by 128.5% during the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company's stock valued at $152,000 after purchasing an additional 2,892 shares in the last quarter. New York State Teachers Retirement System lifted its position in Hims & Hers Health by 95.2% during the first quarter. New York State Teachers Retirement System now owns 194,795 shares of the company's stock valued at $5,756,000 after purchasing an additional 94,983 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Hims & Hers Health during the fourth quarter valued at $1,230,000. Finally, Fifth Third Bancorp lifted its position in Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after purchasing an additional 961 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the sale, the insider directly owned 169,940 shares of the company's stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 2,100 shares of the business's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total value of $120,792.00. Following the sale, the insider directly owned 278,654 shares in the company, valued at $16,028,178.08. The trade was a 0.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,396,090 shares of company stock valued at $71,927,627. Insiders own 13.71% of the company's stock.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent analyst reports. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Piper Sandler reissued a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Truist Financial decreased their price target on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a report on Monday, August 18th. Finally, Bank of America raised their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Price Performance

Shares of HIMS stock traded up $0.57 during trading hours on Friday, hitting $44.53. The stock had a trading volume of 27,930,748 shares, compared to its average volume of 34,221,508. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The stock's 50-day moving average price is $51.71 and its two-hundred day moving average price is $45.81. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 3.01 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same period last year, the firm posted $0.06 earnings per share. The company's revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.